Welcome to our dedicated page for 4D Molecular Therapeutics SEC filings (Ticker: FDMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking gene-therapy R&D costs, milestone contingencies, and patent updates in 4D Molecular Therapeutics’ (FDMT) SEC documents can feel like decoding a lab notebook. Each 10-K spans hundreds of pages of scientific detail and risk factors, while surprise 8-Ks announce critical clinical data the moment it hits EDGAR. Missing one paragraph could mean overlooking a cash-runway warning or a pivotal FDA designation.
Stock Titan solves that problem. Our AI reads every 4D Molecular Therapeutics annual report 10-K simplified, 4D Molecular Therapeutics quarterly earnings report 10-Q filing, and 4D Molecular Therapeutics 8-K material events explained within minutes, then serves plain-English summaries, trend visuals, and red-flag alerts. Need to monitor 4D Molecular Therapeutics insider trading Form 4 transactions? Receive 4D Molecular Therapeutics Form 4 insider transactions real-time on your dashboard. Wondering how executives are paid? The platform highlights key tables in the 4D Molecular Therapeutics proxy statement executive compensation so you can compare R&D bonuses to peer benchmarks.
Whether you're modeling trial costs or tracking the founders’ share sales, our coverage includes every filing type—10-K, 10-Q, 8-K, S-3, S-8, and more—updated the moment FDMT submits to EDGAR. Practical use cases include spotting cash-burn trends before a capital raise, flagging aerosolized AAV clinical milestones buried in MD&A, and interpreting 4D Molecular Therapeutics earnings report filing analysis without wading through biotech jargon. In short, understanding 4D Molecular Therapeutics SEC documents with AI is no longer a scientific experiment.
Form 4 overview: On 06/17/2025, 4D Molecular Therapeutics, Inc. (FDMT) granted director Jacob Chacko a stock option covering 22,500 common shares at an exercise price of $4.15 per share. The filing lists no sales or open-market purchases of the company’s equity; the only transaction disclosed is the option award delivered under the company’s non-employee director compensation program.
Vesting terms: One-third of the option becomes exercisable on 06/17/2026, with the remainder vesting in equal monthly installments until fully vested on 06/17/2028. The award also accelerates to 100% vesting upon a Change in Control, as defined in FDMT’s 2020 Incentive Award Plan.
Ownership impact: Following the grant, Chacko’s derivative-security holdings rise to 22,500 options. No non-derivative common-stock holdings are reported in Table I, suggesting the director currently holds no directly owned FDMT shares or that such holdings were unchanged.
Investor takeaway: The transaction is a routine equity-based compensation grant aimed at aligning director incentives with shareholder interests. It does not involve cash outlay by the company today, carries a 10-year life (expiring 06/16/2035), and is unlikely to materially affect FDMT’s share count or near-term financials.
Form Type: Form 4
Company: 4D Molecular Therapeutics, Inc. (FDMT)
Reporting Person: Susannah Gray, independent director
On 17 June 2025, Ms. Gray received an automatic non-employee director stock-option grant covering 22,500 shares of FDMT common stock. The option has an exercise price of $4.15 per share, identical to the market price on the grant date under the company’s equity plan. No shares were purchased or sold on the open market; the filing merely records the award of a derivative security.
Vesting schedule:
- 1/3 of the option (7,500 shares) vests on 17 June 2026.
- The remaining 15,000 shares vest in equal monthly installments through 17 June 2028.
- Accelerated vesting applies if a Change in Control (per the 2020 Incentive Award Plan) occurs before full vesting.
Following the grant, Ms. Gray’s beneficial ownership in derivative securities totals 22,500 options, all held directly. No other equity transactions (purchases, sales, or disposals) were reported, and the filing does not reference any open-market activity or additional holdings.
The filing is routine for director compensation and does not include earnings data, cash transactions, or changes in company fundamentals. Investors should view it largely as an administrative disclosure of annual board compensation rather than a signal of trading intent.
4D Molecular Therapeutics (FDMT) filed a Form 4 reporting that director Shawn Cline Tomasello received an automatic, non-employee director stock-option grant on 06/17/2025.
The award comprises 22,500 stock options with an exercise price of $4.15. Vesting occurs as follows: one-third on 06/17/2026, with the remaining two-thirds vesting in equal monthly installments through 06/17/2028. All options vest immediately upon a change-in-control, and they expire on 06/16/2035. The filing shows 22,500 derivative securities beneficially owned after the transaction. No open-market acquisitions or dispositions of common shares were reported.
4D Molecular Therapeutics (FDMT) – Form 4 filing: Director Charles Theuer received an automatic grant of 22,500 stock options on 17 June 2025 under the company’s non-employee director compensation program.
The options carry a $4.15 exercise price and a 10-year term expiring 16 June 2035. Vesting is staggered: 33% on 17 June 2026, with the balance vesting in equal monthly installments through 17 June 2028. All unvested shares vest immediately if a change-in-control occurs.
After the grant, the reporting person holds 22,500 derivative securities directly. No open-market purchases or sales were reported, and there were no changes in non-derivative holdings. The disclosure is routine and primarily reflects standard director equity compensation designed to align incentives with shareholder interests.
Form 4 filing for 4D Molecular Therapeutics (FDMT) reports a routine non-derivative insider transaction dated 06/17/2025.
- Reporting person: Nancy Miller-Rich, independent director.
- Transaction: Automatic grant of 22,500 stock options (right to buy common shares) at an exercise price of $4.15 per share.
- Vesting schedule: 1/3 vests on 06/17/2026; the remainder vests monthly until fully vested on 06/17/2028, or sooner upon a change-of-control event.
- Expiration: 06/16/2035.
- Post-transaction holdings: 22,500 derivative securities reported as directly held.
No sales or purchases of already-issued common stock occurred, and the filing contains no financial performance data. The grant stems from the company’s standard non-employee director compensation program and does not indicate a shift in corporate strategy or insider sentiment.
Form 4 filed for 4D Molecular Therapeutics, Inc. (FDMT) reports a routine stock-option grant to director John F. Milligan on 06/17/2025. The award covers 33,750 options to purchase common shares at an exercise price of $4.15. The options were automatically granted under the company’s non-employee director compensation program.
Vesting is structured as follows:
- One-third (11,250 options) vests on 06/17/2026
- Remaining options vest in equal monthly installments until fully vested on 06/17/2028
- All options accelerate to full vesting upon a qualifying Change in Control
Following the grant, Milligan beneficially owns 33,750 derivative securities. No open-market purchases or sales of common stock were reported, and there is no cash outlay for the director at grant date. Investors should view this filing as standard governance practice rather than a signal of immediate financial impact.
FAQ
What is the current stock price of 4D Molecular Therapeutics (FDMT)?
What is the market cap of 4D Molecular Therapeutics (FDMT)?
What is the primary focus of 4D Molecular Therapeutics Inc.?
What technology underpins 4DMT's product development?
Which therapeutic areas does 4D Molecular Therapeutics target?
How does 4DMT differentiate itself from other gene therapy companies?
What are the advantages of using AAV vectors in gene therapy?
How does 4DMT address the issue of treatment burden for patients?
What stages are 4DMT's product candidates currently in?
